Critical Congenital Heart Disease Detection in the Screening Era: Do Not Neglect the Examination!

AJP Rep. 2021 Apr;11(2):e84-e90. doi: 10.1055/s-0041-1727275. Epub 2021 Jun 16.

Abstract

Pulse oximetry oxygen saturation (SpO 2 )-based critical congenital heart disease (CCHD) screening is effective in detection of cyanotic heart lesions. We report a full-term male infant with normal perfusion who had passed the CCHD screening at approximately 24 hours after birth with preductal SpO 2 of 99% and postductal SpO 2 of 97%. Detection of a loud systolic cardiac murmur before discharge led to the diagnosis of pulmonary atresia (PA) with ventricular septal defect (PA-VSD) by echocardiogram. The infant was transferred to a tertiary care center after initiation of prostaglandin E1 (PGE1) therapy. Throughout the initial course, he was breathing comfortably without respiratory distress or desaturations on pulse oximetry. We believe that this is the first documented report of PA missed by CCHD screening. Thorough and serial clinical examinations of the newborn infant proved vital in the timely diagnosis of this critical disease. We review the hemodynamics and the recent literature evaluating utility of CCHD screening in the diagnosis of PA-VSD. Pulse oximetry-based CCHD screening should be considered a tool to enhance CCHD detection with an emphasis on detailed serial physical examinations in newborn infants.

Keywords: CCHD screening; PA-VSD; congenital heart disease; critical congenital heart disease; false negative; newborn; oximetry screening; pulmonary atresia; pulse oximetry; pulse oximetry screening.

Publication types

  • Case Reports